According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...

A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...

A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...

The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

The LEGEND trial showed a 62% complete response (CR) rate with the non-viral gene therapy at six months in NMIBC patients who ...

Growth hormone receptor (GHR) signaling in bladder cancer is associated with advanced tumor stages and poor survival outcomes. High GHR expression in tumors up-regulates genes involved in drug ...

Minze Health announced that it entered into a three-year agreement with Medtronic to commercialize its overactive bladder ...

Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...